

1088 **SUPPLEMENATARY FIGURES**

1089

1090 **FIGURE S1 Southern blot analysis of *T. brucei* genomic DNA, using *TbINO1***

1091 **ORF as a probe.** The genomic DNA was digested with several restriction enzymes  
1092 and analysed by Southern blotting using a fluorescein labelled *INO1* ORF as the  
1093 probe, as described in Experimental Procedures. Lane 1. *NcoI*, Lane 2. *SpeI*, Lane 3.  
1094 *AfIII/SacII*, Lane 4. *EcoRV*. Shown below the autoradiogram is a schematic of the  
1095 predicted restriction enzyme cut sites within the *INO1* ORF and adjacent UTR's.  
1096 NB. There was no restriction site predicted within the ORF or adjacent UTR's for  
1097 *SpeI*.

1098

1099 **FIGURE S2 Deamination of lipid samples from *in vivo* labelling.** Cells were

1100 labelled with [<sup>3</sup>H]-glucose (Lanes 1 and 2) or [<sup>3</sup>H]-mannose (Lane 3), lipids extracted  
1101 and an aliquot of these lipids analysed by HPTLC (Lane 1 and 3 respectively) as  
1102 detailed in Experimental Procedures. Lipids from each labelling were also subjected  
1103 to deamination and butanol water partitioning, the resulting lipid products from the  
1104 [<sup>3</sup>H]-glucose labelling sample were analysed by HPTLC (Lane 2). NB. As  
1105 scintillation counting of the butanol and aqueous fractions from the deamination of  
1106 lipids from the [<sup>3</sup>H]-mannose labelling (see Supplementary Data Table 1) showed that  
1107 there was no [<sup>3</sup>H]-lipid reaction products present, therefore HPTLC of the butanol  
1108 phase was not performed.

1109

1110 **FIGURE S3 sVSG and deglycosylation analysis of samples from *in vivo* labelling.**

1111 Panel A, cells were labelled with [<sup>3</sup>H]-glucose and sVSG isolated. This sVSG was  
1112 deglycosylated with PNGaseF, proteins were separated on SDS-PAGE and detected

1113 by coomassie staining (Lanes 1 and 2) or fluorography (Lanes 3 and 4). Lanes 1 and 3  
1114 show undeglycosylated sVSG, Lanes 2 and 4 show deglycosylated sVSG. Panel B,  
1115 wild type cells were labelled in the presence of tunicamycin and the proteins separated  
1116 by SDS-PAGE. Detection was either by coomassie blue staining (Panel B) or by  
1117 fluorography (Panel C). Lane 1, [<sup>3</sup>H]-mannose pulse labelling, Lane 2 [<sup>3</sup>H]-mannose  
1118 pulse-chase labelling, Lane 3, [<sup>3</sup>H]-glucose pulse labelling, Lane 4, [<sup>3</sup>H]-glucose  
1119 pulse-chase labelling

1120

1121 **FIGURE S4 Analysis of exchange reaction with GPI-VSG as substrate.** Cells  
1122 were labelled with either [<sup>3</sup>H]-mannose, [<sup>3</sup>H]-glucose or [<sup>3</sup>H]-myristate in the  
1123 presence or absence of cycloheximide. Proteins were separated by SDS-PAGE,  
1124 proteins were detected by coomassie blue staining (Lanes 1 to 6), labelled proteins  
1125 detected by fluorography (Lanes 7 to 12). Lane 1 and 7, [<sup>3</sup>H]-mannose labelling  
1126 without cycloheximide; Lane 2 and 8, [<sup>3</sup>H]-mannose labelling with cycloheximide;  
1127 Lane 3 and 9, [<sup>3</sup>H]-glucose labelling without cycloheximide; Lane 4 and 10, [<sup>3</sup>H]-  
1128 glucose labelling with cycloheximide; Lane 5 and 11 [<sup>3</sup>H]-myristate labelling without  
1129 cycloheximide; Lane 6 and 12, [<sup>3</sup>H]-myristate labelling with cycloheximide.


1130

1131


1132

	Deamination		Negative	
	Butanol	Aqueous	Butanol	aqueous
Mannose	7	93	94	6
Glucose	96	4	92	8

**Table S1 Deamination of lipid samples from *in vivo* labelling.** Cells were labelled with [<sup>3</sup>H]-glucose or [<sup>3</sup>H]-mannose, lipids extracted, deaminated and subjected to butanol water partitioning. [<sup>3</sup>H]-Levels in the butanol and water phases were determined by scintillation spectrometry and are expressed as a percentage of the total cpm.




**Supplementary Figure 1**




**Supplementary Figure 2**


A)




B)



C)



**Supplementary Figure 3**



**Supplementary Figure 4**